Role of temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: experience at a single institution
- PMID: 20217098
- DOI: 10.1007/s00381-010-1106-1
Role of temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: experience at a single institution
Abstract
Purpose: The purpose of this study was to assess the efficacy of TMZ on diffuse brainstem glioma, either concomitant with radiotherapy or as an adjuvant treatment after radiotherapy in children.
Methods and materials: Eighteen children (median age at diagnosis was 8.3 years) meet the following criteria: (1) newly diagnosed diffuse brainstem glioma; (2) aged less than 18 years old, which were treated with TMZ at Taipei Veterans General Hospital from January 2004 to December 2008. They were divided into two groups according to treatment modalities: a radiotherapy alone followed by adjuvant TMZ (RT+TMZ) group received conventional radiation after initial diagnosis, and a concomitant chemoradiotherapy followed by adjuvant TMZ (CCRT+TMZ) group received concurrent chemotherapy during radiation with TMZ (75 mg/M(2)/day). After completion of the radiotherapy, TMZ (150 mg/M(2)) was administered once per day for five consecutive days for all enrolled patients in each 28-day cycle. We evaluated the progression-free survival in both groups of patients.
Results: There were 10 patients in RT+TMZ group and eight in CCRT+TMZ group. All patients experienced progression of disease. Twelve patients (75%) died, and all deaths were attributed to the disease progression. The median progression-free survival (PFS) was 7.4 months for the RT+TMZ group and 6.4 months for the CCRT+TMZ group. The 6-month and 1-year PFS in the RT+TMZ group were 70% (SD 14%) and 30% (SD 14%), respectively, and in the CCRT+TMZ group, they were 50% (SD 17%) and 0%, respectively. The log-rank test in PFS between the two groups was not statistically significant.
Conclusions: In this study, CCRT with TMZ followed by adjuvant TMZ did not result in a better outcome when compared with RT alone followed by adjuvant TMZ. In addition, TMZ either as adjuvant therapy or as CCRT did not improve the prognosis of the patients with newly diagnosed diffuse brainstem glioma.
Similar articles
-
Temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: a broken promise?J Chemother. 2015 Feb;27(2):106-10. doi: 10.1179/1973947814Y.0000000228. Epub 2014 Dec 2. J Chemother. 2015. PMID: 25466729
-
Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma.Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):113-8. doi: 10.1016/j.ijrobp.2009.04.031. Epub 2009 Aug 3. Int J Radiat Oncol Biol Phys. 2010. PMID: 19647954 Clinical Trial.
-
Temozolomide after radiotherapy in recurrent "low grade" diffuse brainstem glioma in adults.J Neurooncol. 2014 Dec;120(3):581-6. doi: 10.1007/s11060-014-1589-9. Epub 2014 Aug 20. J Neurooncol. 2014. PMID: 25139026
-
Temozolomide for malignant primary spinal cord glioma: an experience of six cases and a literature review.J Neurooncol. 2011 Jan;101(2):247-54. doi: 10.1007/s11060-010-0249-y. Epub 2010 Jun 5. J Neurooncol. 2011. PMID: 20526650 Review.
-
The Prognostic Impact of Radiotherapy in Conjunction with Temozolomide in Diffuse Intrinsic Pontine Glioma: A Systematic Review and Meta-Analysis.World Neurosurg. 2021 Apr;148:e565-e571. doi: 10.1016/j.wneu.2021.01.024. Epub 2021 Jan 19. World Neurosurg. 2021. PMID: 33476781
Cited by
-
Ancestry and frequency of genetic variants in the general population are confounders in the characterization of germline variants linked to cancer.BMC Med Genet. 2020 May 6;21(1):92. doi: 10.1186/s12881-020-01033-x. BMC Med Genet. 2020. PMID: 32375678 Free PMC article.
-
Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma.J Neurooncol. 2012 Jan;106(2):399-407. doi: 10.1007/s11060-011-0681-7. Epub 2011 Aug 20. J Neurooncol. 2012. PMID: 21858607 Clinical Trial.
-
Genetic and immune features of resectable malignant brainstem gliomas.Oncotarget. 2017 Jul 28;8(47):82571-82582. doi: 10.18632/oncotarget.19653. eCollection 2017 Oct 10. Oncotarget. 2017. PMID: 29137285 Free PMC article.
-
Clinical management and outcome of histologically verified adult brainstem gliomas in Switzerland: a retrospective analysis of 21 patients.J Neurooncol. 2014 Jun;118(2):321-328. doi: 10.1007/s11060-014-1434-1. Epub 2014 Apr 16. J Neurooncol. 2014. PMID: 24736829
-
DIPG in Children - What Can We Learn from the Past?Front Oncol. 2015 Oct 21;5:237. doi: 10.3389/fonc.2015.00237. eCollection 2015. Front Oncol. 2015. PMID: 26557503 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources